Abstracts tagged "Pulmonary Involvement"

Abstract Number: 378 • 2017 ACR/ARHP Annual Meeting
Musculoskeletal Features in Copa Syndrome
William B. Lapin¹, Monica Marcus², Andrea A. Ramirez³, Marietta M. de Guzman³ and Levi B. Watkin^4,5, ¹Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Pediatric Immunology, Allergy and Rheumatology, Texas Children's Hospital, Houston, TX, ³Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ⁵Texas Children's Hospital, Center for Human Immunobiology, Houston, TX
Background/Purpose: COPA syndrome is a newly discovered primary immunodeficiency resulting in immune dysregulation showing autosomal dominant inheritance with incomplete penetrance. Its name is derived from…
Abstract Number: 2980 • 2017 ACR/ARHP Annual Meeting
Chemokine CCL21 As a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis
Anna-Maria Hoffmann-Vold¹, Roger Hesselstrand², Håvard Fretheim¹, Thor Ueland¹, Arne K Andreassen¹, Oyvind Midtvedt¹, Torhild Garen¹, Pål Aukrust¹, John A Belperio³ and Øyvind Molberg¹, ¹Oslo University Hospital, Oslo, Norway, ²Lund University, Lund, Sweden, ³University of California, Los Angeles, Los Angeles, CA
Background/Purpose : Systemic sclerosis (SSc) is a major cause of pulmonary arterial hypertension (PAH). Murine models indicate key roles of chemokines CCL19/21 and their receptor…
Abstract Number: 730 • 2017 ACR/ARHP Annual Meeting
The Association of Pulmonary Hypertension with Isolated Nucleolar Serum Autoantibodies in Systemic Sclerosis
Kathleen Aren¹, Mary A. Carns¹, Michael Cuttica², Julia (Jungwha) Lee³, Virginia D. Steen⁴ and Monique Hinchcliff⁵, ¹Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ²Northwestern University, Feinberg School of Medicine, Division of Pulmonary and Critical Care, Chicago, IL, ³Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ⁵Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Serum antibodies are used to identify SSc patients who may be at higher risk for SSc-PH. The Pulmonary Hypertension Assessment and Recognition of Outcomes…
Abstract Number: 752 • 2017 ACR/ARHP Annual Meeting
Role of the Six-Minute Walk Test in Systemic Sclerosis: Five Years Evolution
Els Vandecasteele¹, Karin Melsens², Filip De Keyser³, Michel De Pauw⁴, Ellen Deschepper⁵, Saskia Decuman⁶, Yves Piette², Kristof Thevissen⁷, Guy Brusselle⁸ and Vanessa Smith³, ¹Dep of Cardiology, University Hospital Ghent, Ghent, Belgium, ²Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, Ghent, Belgium, ³Ghent University, Department of Internal Medicine, Ghent, Belgium, Ghent, Belgium, ⁴Dep of cardiology, University Hospital Ghent, Ghent, Belgium, ⁵Biostatistics Unit, UGent, Ghent, Belgium, ⁶Department of Internal Medicine, Ghent University, Ghent, Belgium, ⁷University Hospital Ghent, Ghent, Belgium, ⁸Gent University, Gent, Belgium
TitleRole of the Six-Minute Walk Test in Systemic Sclerosis: five years evolution. Background/Purpose: Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the leading…
Abstract Number: 105 • 2017 Pediatric Rheumatology Symposium
Isolated Pediatric Pulmonary Capillaritis: A Comprehensive Single-Center Review of Disease Course, Management, and Prognosis
William Lapin¹, Saimun Singla², Eyal Muscal³ and Manuel Silva-Carmona⁴, ¹Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Department Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Department of Pediatrics, Pulmonology Section, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Pediatric diffuse alveolar hemorrhage (DAH) is a life-threatening disorder characterized by pulmonary hemorrhage and respiratory insufficiency. Histologically, DAH with capillary inflammation is known as…
Abstract Number: 835 • 2016 ACR/ARHP Annual Meeting
A Normal Pulmonary Diffusion Capacity Is Rare in Pulmonary Artery Hypertension in Systemic Sclerosis
Rebecca Overbury¹, Tracy M. Frech², Maureen Murtaugh³, Virginia D. Steen⁴ and PHAROS investigators, ¹Internal Medicine and Pediatrics, University of Utah, Salt Lake City, UT, ²Division of Rheumatology, University of Utah, Salt Lake City, UT, ³University of Utah, Salt Lake, UT, ⁴Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Methods: Results: > 70% (mean 78%) versus 191 patients (94.6%) who had a low DLCO <70% (mean 39%). There was no difference…
Abstract Number: 838 • 2016 ACR/ARHP Annual Meeting
Esophageal Dysmotility and Interstitial Lung Disease in Patients with Scleroderma: A Retrospective Study
Shweta Kishore¹, Santhanam Lakshminarayanan¹, Chia-Ling Kuo² and Ranadeep Mandhadi¹, ¹Division of Rheumatology, University of Connecticut, Farmington, CT, ²Department of Community Medicine and Health Care, University of Connecticut, Farmington, CT
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease with pulmonary involvement seen in 75% of patients and esophageal involvement in 90% of the patients.…
Abstract Number: 972 • 2016 ACR/ARHP Annual Meeting
Outcome of the Scleroderma Population “at Risk” to Develop Pulmonary Hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort Study
Vivien Hsu¹, Virginia D. Steen² and PHAROS Investigators, ¹Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, ²Rheumatology, Georgetown University Medical Center, Washington, DC
ABSTRACT: Background/Purpose: We investigated predictors of outcome, including mortality and cardiopulmonary hospitalizations in the Òat riskÓ group for pulmonary hypertension in PHAROS, a prospective longitudinal…
Abstract Number: 973 • 2016 ACR/ARHP Annual Meeting
Clinical Characterization of Patients with World Health Organization Group 2 Pulmonary Hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Jessica K. Gordon¹, Jackie Szymonifka², Matthew R. Lammi³, Virginia D. Steen⁴ and PHAROS Investigators, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ³Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ⁴Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of death in patients (pts) with Systemic Sclerosis (SSc). The World Health Organization (WHO) classifies PH into…
Abstract Number: 1238 • 2016 ACR/ARHP Annual Meeting
Assessment of Mortality and Healthcare Costs Associated with Systemic Sclerosis with and without Lung Involvement
Karina Raimundo¹, Amanda Farr², Ashley Cole³ and Aryeh Fischer⁴, ¹Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, ²Truven Health Analytics, Cambridge, MA, ³Truven Health Analytics, Bethesda, MD, ⁴Medicine / Center for Lungs and Breathing, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Patients with systemic sclerosis (SSc) are at high risk of developing interstitial lung disease (ILD) and/or pulmonary hypertension (PH). These two lung manifestations are…
Abstract Number: 1344 • 2016 ACR/ARHP Annual Meeting
Characteristics, Treatment and Outcome of Severe Pulmonary Hemorrhage Related to Systemic Disease: French Multicentric Study
Adrien Mirouse¹, Antoine Parrot², Jacques Cadranel³, Eric Mariotte⁴, Julien Mayaux⁵, Nicolas Bréchot⁶, Mathieu Vautier⁷, Etienne de Montmollin⁸, Nicolas de Prost⁹, Patrice Cacoub¹⁰ and David Saadooun¹⁰, ¹Service de médecine interne, Hôpital Saint-Antoine, Paris, France, ²Service de pneumologie, Hôpital Tenon, 75020, France, ³Service de pneumologie, Hôpital Tenon, Paris, France, ⁴Service de réanimation médicale, Hôpital Saint-Louis, Paris, France, ⁵Service de pneumologie et réanimation médicale, Hôpital Pitié-Salpêtrière, Paris, France, ⁶Service de réanimation médicale, Hôpital Pitié-Salpêtrière, Paris, France, ⁷Service de médecine interne, CHU de Caen, Caen, France, ⁸Service de réanimation médicale, Hôpital Delafontaine, Saint-Denis, France, ⁹Service de réanimation médicale, Hôpital Henri Mondor, Créteil, France, ¹⁰Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et d’Immunologie clinique, DHU i2B, Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France
Background/Purpose: pulmonary hemorrhage (PH) may complicate systemic disease. The main objective of this study was to describe characteristics, treatment and outcome of patients presenting severe…
Abstract Number: 1491 • 2016 ACR/ARHP Annual Meeting
M-Ficolin and MAp44 As Potential Markers of Subclinical Cardiovascular Comorbidity; Cardiac Evaluation By Coronary Computer Tomography and Myocardial Deformation of Left Ventricle in Early Rheumatoid Arthritis Patients
Ida G. Louw¹, Christian G. Ammitzböll², Brian Bridal Løgstrup³, Jesper Blegvad-Nissen⁴, Grazina Urbonaviciene⁴, Trine Bay Laurberg⁴, Mette Herly⁵, Agnete H. Nielsen⁴, Steffen Thiel⁶ and Torkell Ellingsen⁵, ¹University of Southern Denmark, Odense, DK, Odense, Denmark, ²Department of Rheumatology, Aarhus University Hospital, Aarhus, DK, Aarhus, Denmark, ³Department of Cardiology, Skejby, Aarhus University Hospital, Aarhus, DK, Aarhus, Denmark, ⁴Diagnostic Centre, University Research Clinic for Innovative Patient Pathways, Silkeborg Regional Hospital, DK, Silkeborg, Denmark, ⁵Department of Rheumatology, Odense University Hospital, Odense, DK, Odense, Denmark, ⁶Institute of Biomedicine, Aarhus University, Aarhus, DK, Aarhus, Denmark
Background/Purpose: 79 DMARD-naïve RA patients with a disease duration < 6 months were included from an inception cohort. Clinical variables, plasma- and serum-M-ficolin and MAp44…
Abstract Number: 1896 • 2016 ACR/ARHP Annual Meeting
Efficacy of Pulmonary Arterial Hypertension-Specific Drugs Combination Therapy in Survival of Patients with Pulmonary Arterial Hypertension Associated with Systemic Sclerosis and Other Connective Tissue Diseases
Sumiaki Tanaka¹, Yu Matsueda¹, Gakuro Abe², Jun Okada³ and Shunsei Hirohata¹, ¹Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ²Kitasato University School of Medicine, Sagamihara, Japan, ³Nutritional management, Kitasato Junior Collage of health and Hygienic Sciences, Minami-Uonuma, Japan
Background/Purpose: Survival of patients with pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD), especially systemic sclerosis (SSc), is poorer than that of patients…
Abstract Number: 2158 • 2016 ACR/ARHP Annual Meeting
Serum Uric Acid Is Positively Associated with Pulmonary Function in Korean Health Screening Examinees: A Cross-Sectional Study
Joong Kyong Ahn¹, Jiwon Hwang², Jae-Uk Song³, Hyemin Jeong⁴, Ji Young Chae⁵, Hyungjin Kim⁴, Hoon-Suk Cha⁴ and Eun-Mi Koh⁴, ¹Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Department of Medicine, National Police Hospital, Seoul, Korea, The Republic of, ³Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea, The Republic of, ⁴Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁵Departement of Internal Medicine, Bundang Jesaeng General Hospital, Seongnam, Korea, The Republic of
Background/Purpose: Serum uric acid (SUA) has been shown to be a powerful endogenous antioxidant in the body. The double-edged characteristics of serum uric acid (SUA)…
Abstract Number: 2201 • 2016 ACR/ARHP Annual Meeting
Self-Reported Breathlessness on Exertion Is Associated with Poor Outcomes Among Women with Systemic Lupus Erythematosus (SLE)
Patricia P. Katz¹, Sofia Pedro², Robert S. Katz³, Frederick Wolfe⁴ and Kaleb Michaud⁵, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Rush University Medical Center, Chicago, IL, ⁴National Data Bank, Wichita, KS, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Breathlessness is often considered as a predictor of functional outcomes in pulmonary disease, but has not been examined in SLE. Methods: Data were from…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].